Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
TG Therapeutics announces preclinical data for TG-1701 » 09:18
06/22/20
06/22
09:18
06/22/20
09:18
TGTX

TG Therapeutics

$18.63 /

-0.15 (-0.80%)

TG Therapeutics announced…

TG Therapeutics announced preclinical data presentation for TG-1701, the Company's highly selective, BTK inhibitor, at the 2020 American Association for Cancer Research annual meeting, being held virtually. Title: TG-1701, a novel irreversible Bruton's kinase inhibitor, does not inhibit anti-CD20-driven ADCC and ADCP in vitro, and cooperates with the glycoengineered anti-CD20 mAb, ublituximab, in in vivo mantle cell lymphoma models: In vitro and in vivo studies were undertaken to evaluate the activity of TG-1701 alone and in combination with ublituximab and umbralisib in models of lymphoma: TG-1701 showed greater selectivity for BTK than, and similar activity to, ibrutinib in mantel cell lymphoma models; TG-1701, in contrast to ibrutinib, did not block ublituximab-driven antibody-dependent cellular cytotoxicity or antibody-dependent cell phagocytosis in vitro; In vivo xenograft studies suggested that TG-1701 synergized with the U2 combination, resulting in greater anti-tumor activity than either TG-1701 or U2 alone.

ShowHide Related Items >><<
TGTX TG Therapeutics
$18.63 /

-0.15 (-0.80%)

TGTX TG Therapeutics
$18.63 /

-0.15 (-0.80%)

06/12/20 H.C. Wainwright
TG Therapeutics data presentations at EHA 'compelling,' says H.C. Wainwright
05/18/20 B. Riley FBR
TG Therapeutics price target raised to $37 from $29 at B. Riley FBR
05/17/20 B. Riley FBR
TG Therapeutics price target raised to $37 from $29 at B. Riley FBR
05/06/20 Cantor Fitzgerald
TG Therapeutics price target raised to $35 from $19 at Cantor Fitzgerald
TGTX TG Therapeutics
$18.63 /

-0.15 (-0.80%)

TGTX TG Therapeutics
$18.63 /

-0.15 (-0.80%)

TGTX TG Therapeutics
$18.63 /

-0.15 (-0.80%)

Hot Stocks
TG Therapeutics completes rolling submission of NDA for umbralisib » 07:04
06/17/20
06/17
07:04
06/17/20
07:04
TGTX

TG Therapeutics

$18.17 /

+0.01 (+0.06%)

TG Therapeutics announced…

TG Therapeutics announced the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration requesting accelerated approval of umbralisib, the Company's investigational once-daily, oral, dual inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with previously treated marginal zone lymphoma and follicular lymphoma. The FDA previously granted umbralisib breakthrough therapy designation for MZL and orphan drug designation for MZL and FL. The UNITY- NHL trial is a multicenter, open-label Phase 2b trial. The MZL cohort was designed to evaluate the safety and efficacy of single agent umbralisib, in patients with MZL who have received at least one prior anti-CD20 regimen. In February of 2019, the Company announced that the primary endpoint of overall response rate as determined by Independent Review Committee was met for all treated MZL patients. The results met the Company's target guidance of 40-50% ORR. Interim safety and efficacy data from the MZL cohort were presented in oral presentations in 2019 at the American Association for Cancer Research annual meeting, the American Society of Clinical Oncology annual meeting and the International Conference on Malignant Lymphoma. The FL cohort was designed to evaluate the safety and efficacy of single agent umbralisib in patients with FL who have received at least two prior lines of therapy, including an anti-CD20 regimen and an alkylating agent. In October of 2019, the Company announced that the primary endpoint of ORR as determined by IRC was met for all treated FL patients. The results met the Company's prespecified response target of 40-50% ORR.

ShowHide Related Items >><<
TGTX TG Therapeutics
$18.17 /

+0.01 (+0.06%)

TGTX TG Therapeutics
$18.17 /

+0.01 (+0.06%)

06/12/20 H.C. Wainwright
TG Therapeutics data presentations at EHA 'compelling,' says H.C. Wainwright
05/18/20 B. Riley FBR
TG Therapeutics price target raised to $37 from $29 at B. Riley FBR
05/17/20 B. Riley FBR
TG Therapeutics price target raised to $37 from $29 at B. Riley FBR
05/06/20 Cantor Fitzgerald
TG Therapeutics price target raised to $35 from $19 at Cantor Fitzgerald
TGTX TG Therapeutics
$18.17 /

+0.01 (+0.06%)

TGTX TG Therapeutics
$18.17 /

+0.01 (+0.06%)

TGTX TG Therapeutics
$18.17 /

+0.01 (+0.06%)

Recommendations
TG Therapeutics data presentations at EHA 'compelling,' says H.C. Wainwright » 11:19
06/12/20
06/12
11:19
06/12/20
11:19
TGTX

TG Therapeutics

$16.72 /

-0.05 (-0.30%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Edward White noted that TG Therapeutics announced presentations at the European Hematology Association, or EHA, annual congress with data that he described as "compelling." The analyst, who said he continues to expect TG-1701 to be "an important component of a wholly-owned triplet therapy," keeps a Buy rating and $32 price target on TG Therapeutics shares.

ShowHide Related Items >><<
TGTX TG Therapeutics
$16.72 /

-0.05 (-0.30%)

TGTX TG Therapeutics
$16.72 /

-0.05 (-0.30%)

05/18/20 B. Riley FBR
TG Therapeutics price target raised to $37 from $29 at B. Riley FBR
05/17/20 B. Riley FBR
TG Therapeutics price target raised to $37 from $29 at B. Riley FBR
05/06/20 Cantor Fitzgerald
TG Therapeutics price target raised to $35 from $19 at Cantor Fitzgerald
05/05/20 B. Riley FBR
TG Therapeutics price target raised to $29 from $25 at B. Riley FBR
TGTX TG Therapeutics
$16.72 /

-0.05 (-0.30%)

TGTX TG Therapeutics
$16.72 /

-0.05 (-0.30%)

TGTX TG Therapeutics
$16.72 /

-0.05 (-0.30%)

Hot Stocks
TG Therapeutics announces data presentations at EHA Annual Congress » 07:15
06/12/20
06/12
07:15
06/12/20
07:15
TGTX

TG Therapeutics

$16.77 /

-0.93 (-5.25%)

TG Therapeutics announced…

TG Therapeutics announced data presentations at the 25th European Hematology Association annual congress including data from a Phase 1 study evaluating TG-1701, the Company's once daily, selective, BTK inhibitor, as monotherapy and in combination with umbralisib and ublituximab in relapsed/refractory chronic lymphocytic leukemia and lymphoma, as well as long term data from a Phase 1/1b study evaluating the combination of umbralisib and ibrutinib in relapsed/refractory CLL and mantle cell lymphoma. Presentation Title: Safety and activity of the once daily selective bruton tyrosine kinase inhibitor TG-1701 in patients with chronic lymphocytic leukemia and lymphoma: This presentation includes interim data from a Phase 1 parallel dose-escalation study of TG-1701 monotherapy and TG-1701 in combination with U2 in 82 patients with relapsed/refractory B-cell malignancies. Sixty-nine patients were treated with single agent TG-1701, of which 25 patients were treated in the monotherapy dose escalation portion of the study and received TG-1701 at doses that ranged from 100mg to 400mg once daily, and 44 patients were treated with 200mg of TG-1701 in the monotherapy dose expansion cohort. An additional 13 patients were treated in the TG-1701 plus U2 dose escalation portion of the study. Safety and efficacy highlights include: TG-1701 monotherapy exhibited an encouraging preliminary safety profile across all dose levels evaluated with only 3% of patients having a dose reduction due to treatment-related adverse events, with no treatment discontinuations due to AEs in the monotherapy cohorts. In the monotherapy dose escalation cohort, TG-1701 produced partial responses at all dose levels evaluated in CLL, MCL, Waldenstrom's macroglobulinemia, and small lymphocytic lymphoma. In the monotherapy dose expansion cohort in which TG-1701 was administered at 200mg, 25 patients were evaluable for efficacy with a 92% overall response rate observed in CLL patients, a 33% ORR in MCL patients, and a 86% ORR in WM patients. The combination of TG-1701 plus U2 has been well tolerated and demonstrated encouraging clinical activity with a 77% ORR across all disease types, including complete responses in three patients; dose escalation continues. Presentation Title: Long term results of a Phase I/Ib study of ibrutinib in combination with umbralisib in patients with relapsed/refractory CLL or MCL: This presentation includes updated long term data from a Phase 1/1b study of patients with relapsed or refractory CLL or MCL treated with umbralisib in combination with ibrutinib. Data from this trial were previously published in Lancet Haematology in December 2018. As of the updated data cutoff, 42 patients were evaluable for safety and efficacy. Safety and efficacy highlights include: With long term follow up median follow-up of 43.5 months, there were no cumulative or recurrent late onset toxicities observed. In relapsed/refractory CLL, the overall response rate was 95% including a 29% complete response rate, and the 4-year Progression-free Survival and Overall Survival were 78% and 90%, respectively In relapsed/refractory MCL, the ORR was 71% with a 24% CR rate, and median PFS and OS were 10.8 and 30.7 months, respectively.

ShowHide Related Items >><<
TGTX TG Therapeutics
$16.77 /

-0.93 (-5.25%)

TGTX TG Therapeutics
$16.77 /

-0.93 (-5.25%)

05/18/20 B. Riley FBR
TG Therapeutics price target raised to $37 from $29 at B. Riley FBR
05/17/20 B. Riley FBR
TG Therapeutics price target raised to $37 from $29 at B. Riley FBR
05/06/20 Cantor Fitzgerald
TG Therapeutics price target raised to $35 from $19 at Cantor Fitzgerald
05/05/20 B. Riley FBR
TG Therapeutics price target raised to $29 from $25 at B. Riley FBR
TGTX TG Therapeutics
$16.77 /

-0.93 (-5.25%)

TGTX TG Therapeutics
$16.77 /

-0.93 (-5.25%)

TGTX TG Therapeutics
$16.77 /

-0.93 (-5.25%)

Over a month ago
Hot Stocks
TG Therapeutics announces final results of GENUINE Phase 3 study » 08:51
05/29/20
05/29
08:51
05/29/20
08:51
TGTX

TG Therapeutics

$19.74 /

-0.8 (-3.89%)

TG Therapeutics announced…

TG Therapeutics announced the final results from the GENUINE Phase 3 study evaluating the combination of ublituximab, the Company's novel glycoengineered anti-CD20 monoclonal antibody, plus ibrutinib compared to ibrutinib alone in patients with previously treated high-risk chronic lymphocytic leukemia at the 56th American Society of Clinical Oncology annual meeting. Details of the data presentation are included below. Presentation Title: Effect of Adding Ublituximab to Ibrutinib on PFS, ORR, and MRD Negativity in Previously Treated High-Risk Chronic Lymphocytic Leukemia: Final Results of the GENUINE Phase III Study : The GENUINE trial is an open-label, multicenter, randomized, Phase III study in relapsed or refractory high-risk CLL. This presentation includes data from 117 patients treated with either ublituximab plus ibrutinib or ibrutinib alone. As of the cut-off date of September 1, 2019, patients had a median follow-up time of 41.9 months. The primary endpoint for this trial was overall response rate as determined by an independent review committee. The secondary endpoints included progression free survival and complete response rate as determined by an IRC, and undetectable minimal residual disease assessed by central lab. Efficacy and safety highlights include: The addition of ublituximab to ibrutinib compared to ibrutinib monotherapy significantly improved ORR, complete response/complete response with incomplete blood count recovery rate, and increased rates of uMRD in patients with relapsed/refractory CLL with high-risk cytogenetics. At a median follow-up of 41.9 months, median PFS was not reached in the ublituximab plus ibrutinib arm and was 35.9 months in the ibrutinib monotherapy arm, with del17p/TP53mut patients seeing the greatest difference in PFS. The addition of ublituximab to ibrutinib did not significantly alter the known safety profile of ibrutinib however the combination resulted in slightly higher rates of neutropenia and atrial fibrillation.

ShowHide Related Items >><<
TGTX TG Therapeutics
$19.74 /

-0.8 (-3.89%)

TGTX TG Therapeutics
$19.74 /

-0.8 (-3.89%)

05/18/20 B. Riley FBR
TG Therapeutics price target raised to $37 from $29 at B. Riley FBR
05/17/20 B. Riley FBR
TG Therapeutics price target raised to $37 from $29 at B. Riley FBR
05/06/20 Cantor Fitzgerald
TG Therapeutics price target raised to $35 from $19 at Cantor Fitzgerald
05/05/20 B. Riley FBR
TG Therapeutics price target raised to $29 from $25 at B. Riley FBR
TGTX TG Therapeutics
$19.74 /

-0.8 (-3.89%)

TGTX TG Therapeutics
$19.74 /

-0.8 (-3.89%)

TGTX TG Therapeutics
$19.74 /

-0.8 (-3.89%)

Recommendations
TG Therapeutics price target raised to $37 from $29 at B. Riley FBR » 08:50
05/18/20
05/18
08:50
05/18/20
08:50
TGTX

TG Therapeutics

$19.30 /

-0.6 (-3.02%)

B. Riley FBR analyst…

B. Riley FBR analyst Mayank Mamtani raised the firm's price target on TG Therapeutics to $37 from $29 and keeps a Buy rating on the shares. The analyst has increased conviction in ublituximab's value across the oncology and multiple sclerosis franchises. Further, TG's strengthened balance sheet removes a key stock overhang, Mamtani tells investors in a research note.

ShowHide Related Items >><<
TGTX TG Therapeutics
$19.30 /

-0.6 (-3.02%)

TGTX TG Therapeutics
$19.30 /

-0.6 (-3.02%)

05/17/20 B. Riley FBR
TG Therapeutics price target raised to $37 from $29 at B. Riley FBR
05/06/20 Cantor Fitzgerald
TG Therapeutics price target raised to $35 from $19 at Cantor Fitzgerald
05/05/20 B. Riley FBR
TG Therapeutics price target raised to $29 from $25 at B. Riley FBR
05/05/20 H.C. Wainwright
TG Therapeutics price target raised to $32 from $24 at H.C. Wainwright
TGTX TG Therapeutics
$19.30 /

-0.6 (-3.02%)

TGTX TG Therapeutics
$19.30 /

-0.6 (-3.02%)

TGTX TG Therapeutics
$19.30 /

-0.6 (-3.02%)

Recommendations
TG Therapeutics price target raised to $37 from $29 at B. Riley FBR » 20:17
05/17/20
05/17
20:17
05/17/20
20:17
TGTX

TG Therapeutics

$19.30 /

-0.6 (-3.02%)

B. Riley FBR analyst…

B. Riley FBR analyst Mayank Mamtani raised the firm's price target on TG Therapeutics to $37 from $29 and keeps a Buy rating on the shares. The analyst has increased conviction in the valuation of ublituximab.

ShowHide Related Items >><<
TGTX TG Therapeutics
$19.30 /

-0.6 (-3.02%)

TGTX TG Therapeutics
$19.30 /

-0.6 (-3.02%)

05/06/20 Cantor Fitzgerald
TG Therapeutics price target raised to $35 from $19 at Cantor Fitzgerald
05/05/20 B. Riley FBR
TG Therapeutics price target raised to $29 from $25 at B. Riley FBR
05/05/20 H.C. Wainwright
TG Therapeutics price target raised to $32 from $24 at H.C. Wainwright
01/17/20 B. Riley FBR
TG Therapeutics price target raised to $25 from $17 at B. Riley FBR
TGTX TG Therapeutics
$19.30 /

-0.6 (-3.02%)

TGTX TG Therapeutics
$19.30 /

-0.6 (-3.02%)

TGTX TG Therapeutics
$19.30 /

-0.6 (-3.02%)

Options
Unusually active option classes on open May 15th » 09:40
05/15/20
05/15
09:40
05/15/20
09:40
SRNE

Sorrento Therapeutics

$2.63 /

+ (+0.00%)

, MT

ArcelorMittal

$8.43 /

+ (+0.00%)

, RIO

Rio Tinto

$46.54 /

+ (+0.00%)

, TGTX

TG Therapeutics

$19.90 /

+ (+0.00%)

, SLV

iShares Silver Trust

$14.81 /

-0.015 (-0.10%)

, DKNG

DraftKings

$25.29 /

+ (+0.00%)

, QCOM

Qualcomm

$79.86 /

+ (+0.00%)

, GSX

GSX Techedu

$34.88 /

+ (+0.00%)

, GDXJ

VanEck Vectors Junior Gold Miners

$43.35 /

+ (+0.00%)

, OXY

Occidental Petroleum

$13.76 /

+ (+0.00%)

Unusual total active…

Unusual total active option classes on open include: Sorrento Therapeutics (SRNE), ArcelorMittal (MT), Rio Tinto (RIO), TG Therapeutics (TGTX), iShares Silver Trust (SLV), DKNG (DKNG), Qualcomm (QCOM), GSX Techedu (GSX), GDXJ (GDXJ), and Occidental Petroleum (OXY).

ShowHide Related Items >><<
TGTX TG Therapeutics
$19.90 /

+ (+0.00%)

SRNE Sorrento Therapeutics
$2.63 /

+ (+0.00%)

RIO Rio Tinto
$46.54 /

+ (+0.00%)

QCOM Qualcomm
$79.86 /

+ (+0.00%)

OXY Occidental Petroleum
$13.76 /

+ (+0.00%)

MT ArcelorMittal
$8.43 /

+ (+0.00%)

GSX GSX Techedu
$34.88 /

+ (+0.00%)

DKNG DraftKings
$25.29 /

+ (+0.00%)

SRNE Sorrento Therapeutics
$2.63 /

+ (+0.00%)

10/07/19 JMP Securities
Sorrento Therapeutics initiated with an Outperform at JMP Securities
07/23/19 H.C. Wainwright
Sorrento Therapeutics price target lowered to $30 from $40 at H.C. Wainwright
MT ArcelorMittal
$8.43 /

+ (+0.00%)

05/14/20 JPMorgan
ArcelorMittal price target lowered to EUR 8.50 from EUR 9.50 at JPMorgan
05/13/20 Deutsche Bank
ArcelorMittal price target lowered to EUR 14 from EUR 16 at Deutsche Bank
05/12/20 Deutsche Bank
Deutsche Bank backs Buy on ArcelorMittal after MCB offering
05/12/20 UBS
UBS backs Buy on ArcelorMittal after equity issue
RIO Rio Tinto
$46.54 /

+ (+0.00%)

05/11/20 JPMorgan
Rio Tinto price target lowered to 4,560 GBp from 4,730 GBp at JPMorgan
04/30/20 JPMorgan
Rio Tinto price target lowered to 4,730 GBp from 4,870 GBp at JPMorgan
04/23/20 Societe Generale
Rio Tinto price target raised to 4,240 GBp from 4,100 GBp at Societe Generale
04/20/20 JPMorgan
Rio Tinto price target raised to 4,870 GBp from 4,860 GBp at JPMorgan
TGTX TG Therapeutics
$19.90 /

+ (+0.00%)

05/06/20 Cantor Fitzgerald
TG Therapeutics price target raised to $35 from $19 at Cantor Fitzgerald
05/05/20 B. Riley FBR
TG Therapeutics price target raised to $29 from $25 at B. Riley FBR
05/05/20 H.C. Wainwright
TG Therapeutics price target raised to $32 from $24 at H.C. Wainwright
01/17/20 B. Riley FBR
TG Therapeutics price target raised to $25 from $17 at B. Riley FBR
SLV iShares Silver Trust
$14.81 /

-0.015 (-0.10%)

DKNG DraftKings
$25.29 /

+ (+0.00%)

05/14/20
Fly Intel: Top five analyst initiations
05/14/20 Craig-Hallum
DraftKings price target raised to $30 from $25 at Craig-Hallum
05/14/20 Susquehanna
DraftKings initiated with a Positive at Susquehanna
05/05/20
Fly Intel: Top five analyst initiations
QCOM Qualcomm
$79.86 /

+ (+0.00%)

05/04/20
Fly Intel: Top five analyst initiations
05/04/20 KeyBanc
Apple cautious iPhone outlook likely a headwind for chip suppliers, says KeyBanc
05/04/20 Wells Fargo
Qualcomm initiated with an Underweight at Wells Fargo
05/04/20 Wells Fargo
Qualcomm initiated with an Underweight at Wells Fargo
GSX GSX Techedu
$34.88 /

+ (+0.00%)

05/11/20 Barclays
GSX Techedu offered comprehensive rebuttal to short sellers, says Barclays
05/11/20 Nomura Instinet
GSX Techedu price target raised to $40 from $35 at Nomura Instinet
05/07/20 CLSA
GSX Techedu downgraded to Sell from Outperform at CLSA
05/07/20 Citi
GSX Techedu share buyback to offer support, says Citi
GDXJ VanEck Vectors Junior Gold Miners
$43.35 /

+ (+0.00%)

OXY Occidental Petroleum
$13.76 /

+ (+0.00%)

05/07/20
Fly Intel: Top five analyst upgrades
05/07/20 SunTrust
Occidental Petroleum upgraded to Hold from Sell at SunTrust
05/06/20 SunTrust
Occidental Petroleum upgraded to Hold from Sell at SunTrust
05/05/20 Mizuho
Western Midstream price target lowered to $12 from $23 at Mizuho
TGTX TG Therapeutics
$19.90 /

+ (+0.00%)

QCOM Qualcomm
$79.86 /

+ (+0.00%)

OXY Occidental Petroleum
$13.76 /

+ (+0.00%)

GSX GSX Techedu
$34.88 /

+ (+0.00%)

DKNG DraftKings
$25.29 /

+ (+0.00%)

  • 15
    May
  • 12
    May
RIO Rio Tinto
$46.54 /

+ (+0.00%)

QCOM Qualcomm
$79.86 /

+ (+0.00%)

OXY Occidental Petroleum
$13.76 /

+ (+0.00%)

MT ArcelorMittal
$8.43 /

+ (+0.00%)

GSX GSX Techedu
$34.88 /

+ (+0.00%)

TGTX TG Therapeutics
$19.90 /

+ (+0.00%)

SRNE Sorrento Therapeutics
$2.63 /

+ (+0.00%)

RIO Rio Tinto
$46.54 /

+ (+0.00%)

QCOM Qualcomm
$79.86 /

+ (+0.00%)

OXY Occidental Petroleum
$13.76 /

+ (+0.00%)

MT ArcelorMittal
$8.43 /

+ (+0.00%)

DKNG DraftKings
$25.29 /

+ (+0.00%)

TGTX TG Therapeutics
$19.90 /

+ (+0.00%)

SRNE Sorrento Therapeutics
$2.63 /

+ (+0.00%)

SLV iShares Silver Trust
$14.81 /

-0.015 (-0.10%)

RIO Rio Tinto
$46.54 /

+ (+0.00%)

QCOM Qualcomm
$79.86 /

+ (+0.00%)

OXY Occidental Petroleum
$13.76 /

+ (+0.00%)

MT ArcelorMittal
$8.43 /

+ (+0.00%)

GSX GSX Techedu
$34.88 /

+ (+0.00%)

GDXJ VanEck Vectors Junior Gold Miners
$43.35 /

+ (+0.00%)

DKNG DraftKings
$25.29 /

+ (+0.00%)

Syndicate
TG Therapeutics 6M share Spot Secondary priced at $18.00 » 05:58
05/15/20
05/15
05:58
05/15/20
05:58
TGTX

TG Therapeutics

$19.90 /

-0.72 (-3.49%)

The deal size was…

The deal size was increased to 8.5M shares from 6M shares and priced at the bottom of the $18.00-$19.00 range. JPMorgan, Jefferies, Evercore ISI and Cantor Fitzgerald acted as joint book running managers for the offering.

ShowHide Related Items >><<
TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

05/06/20 Cantor Fitzgerald
TG Therapeutics price target raised to $35 from $19 at Cantor Fitzgerald
05/05/20 B. Riley FBR
TG Therapeutics price target raised to $29 from $25 at B. Riley FBR
05/05/20 H.C. Wainwright
TG Therapeutics price target raised to $32 from $24 at H.C. Wainwright
01/17/20 B. Riley FBR
TG Therapeutics price target raised to $25 from $17 at B. Riley FBR
TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

  • 15
    May
TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

On The Fly
Fly Intel: After-Hours Movers » 19:11
05/14/20
05/14
19:11
05/14/20
19:11
YTEN

Yield10 Bioscience

$4.92 /

-0.02 (-0.40%)

, OPRT

Oportun Financial

$6.00 /

-0.25 (-4.00%)

, DENN

Denny's

$8.77 /

-0.035 (-0.40%)

, ACB

Aurora Cannabis

$6.61 /

+0.79 (+13.57%)

, AEYE

AudioEye

$8.88 /

+0.71 (+8.69%)

, NEWR

New Relic

$58.22 /

+1.62 (+2.86%)

, DDS

Dillard's

$22.94 /

-1.15 (-4.77%)

, AMAT

Applied Materials

$54.51 /

+2.98 (+5.78%)

, GLOB

Globant

$111.38 /

+3.1 (+2.86%)

, OCUL

Ocular Therapeutix

$6.01 /

-0.3 (-4.75%)

, REGN

Regeneron

$569.80 /

-7.58 (-1.31%)

, CODX

Co-Diagnostics

$22.19 /

-1.2 (-5.13%)

, FTCH

Farfetch

$15.94 /

+0.35 (+2.25%)

, CVET

Covetrus

$11.25 /

+0.3 (+2.74%)

, ETON

Eton Pharmaceuticals

$5.20 /

+0.03 (+0.58%)

, AUPH

Aurinia Pharmaceuticals

$17.39 /

-0.19 (-1.08%)

, VVI

Viad

$16.65 /

+0.71 (+4.45%)

, TGTX

TG Therapeutics

$19.90 /

-0.72 (-3.49%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
YTEN Yield10 Bioscience
$4.92 /

-0.02 (-0.40%)

VVI Viad
$16.65 /

+0.71 (+4.45%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

OPRT Oportun Financial
$6.00 /

-0.25 (-4.00%)

OCUL Ocular Therapeutix
$6.01 /

-0.3 (-4.75%)

NEWR New Relic
$58.22 /

+1.62 (+2.86%)

GLOB Globant
$111.38 /

+3.1 (+2.86%)

FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

ETON Eton Pharmaceuticals
$5.20 /

+0.03 (+0.58%)

DENN Denny's
$8.77 /

-0.035 (-0.40%)

DDS Dillard's
$22.94 /

-1.15 (-4.77%)

CVET Covetrus
$11.25 /

+0.3 (+2.74%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

AEYE AudioEye
$8.88 /

+0.71 (+8.69%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

YTEN Yield10 Bioscience
$4.92 /

-0.02 (-0.40%)

12/11/19 Ladenburg
Yield10 Bioscience price target lowered to $1 from $7 at Ladenburg
11/18/19 National Securities
Yield10 Bioscience downgraded to Neutral from Buy at National Securities
07/22/19 Aegis
Yield10 Bioscience initiated with a Buy at Aegis
OPRT Oportun Financial
$6.00 /

-0.25 (-4.00%)

04/07/20 BTIG
Oportun Financial price target lowered to $19 from $27 at BTIG
01/17/20 JPMorgan
Oportun Financial downgraded to Neutral on valuation at JPMorgan
01/17/20 JPMorgan
Oportun Financial downgraded to Neutral from Overweight at JPMorgan
12/23/19 BTIG
Oportun Financial price target raised to $27 from $22 at BTIG
DENN Denny's
$8.77 /

-0.035 (-0.40%)

04/08/20 Oppenheimer
Denny's price target lowered to $13 from $27 at Oppenheimer
04/01/20 SunTrust
El Pollo Loco upgraded to Buy from Hold at SunTrust
04/01/20 SunTrust
Denny's upgraded to Buy from Hold at SunTrust
03/20/20 Stephens
Denny's price target lowered to $12 from $19 at Stephens
ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

05/13/20 Cantor Fitzgerald
Aurora Cannabis price target raised to C$22 from C$2.75 at Cantor Fitzgerald
04/08/20 Raymond James
Ontario AG order positive for Canadian cannabis stocks, says Raymond James
02/27/20 Bryan Garnier
Aurora Cannabis downgraded to Sell from Neutral at Bryan Garnier
02/25/20 Needham
Aurora Cannabis initiated with a Hold at Needham
AEYE AudioEye
$8.88 /

+0.71 (+8.69%)

10/24/19 National Securities
AudioEye resumed with a Buy at National Securities
05/31/19 B. Riley FBR
AudioEye selloff brings 'compelling' entry point, syays B. Riley FBR
NEWR New Relic
$58.22 /

+1.62 (+2.86%)

04/27/20 Needham
New Relic price target lowered to $74 from $108 at Needham
04/14/20 Morgan Stanley
New Relic downgraded to Equal Weight amid weaker backdrop at Morgan Stanley
04/14/20 Morgan Stanley
New Relic downgraded to Equal Weight from Overweight at Morgan Stanley
04/06/20 Rosenblatt
New Relic initiated with a Neutral at Rosenblatt
DDS Dillard's
$22.94 /

-1.15 (-4.77%)

05/07/20 Deutsche Bank
Dillard's price target lowered to $18 from $36 at Deutsche Bank
04/30/20 Wedbush
Dillard's price target lowered to $25 from $63 at Wedbush
01/24/20 Odeon Capital
Dillard's initiated with a Sell at Odeon Capital
11/11/19 Deutsche Bank
L Brands downgraded to Hold from Buy at Deutsche Bank
AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

05/12/20 Susquehanna
Applied Materials fundamentals strong ahead of results, says Susquehanna
05/11/20 Cowen
Applied Materials sales trajectory has positive slope, says Cowen
05/08/20 Wells Fargo
Applied Materials price target raised to $60 from $50 at Wells Fargo
04/14/20 Deutsche Bank
Applied Materials share underperformance unwarranted, says Deutsche Bank
GLOB Globant
$111.38 /

+3.1 (+2.86%)

04/29/20 Goldman Sachs
Globant price target lowered to $130 from $165 at Goldman Sachs
04/16/20 Wedbush
Globant price target lowered to $120 from $150 at Wedbush
03/10/20 KeyBanc
Globant downgraded to Sector Weight from Overweight at KeyBanc
02/21/20 Cantor Fitzgerald
Globant price target raised to $120 from $97 at Cantor Fitzgerald
OCUL Ocular Therapeutix
$6.01 /

-0.3 (-4.75%)

05/08/20 Piper Sandler
Ocular Therapeutix long-term opportunity intact, says Piper Sandler
04/29/20 H.C. Wainwright
Ocular Therapeutix price target raised to $10 from $8 at H.C. Wainwright
04/28/20 Piper Sandler
Ocular Therapeutix data warrant discussions with FDA, says Piper Sandler
03/04/20 Piper Sandler
Ocular Therapeutix price target raised to $11 from $7 at Piper Sandler
REGN Regeneron
$569.80 /

-7.58 (-1.31%)

05/14/20 Piper Sandler
Piper 'incrementally positive' on Regeneron shares after fireside chat
05/06/20 Canaccord
Regeneron price target raised to $630 from $575 at Canaccord
05/06/20 BMO Capital
Regeneron price target raised to $525 from $466 at BMO Capital
05/06/20 SVB Leerink
Regeneron price target raised to $622 from $604 at SVB Leerink
CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

03/09/20 H.C. Wainwright
Co-Diagnostics price target raised to $20 from $4 at H.C. Wainwright
03/03/20
Fly Intel: Top five analyst downgrades
03/03/20 Maxim
Co-Diagnostics downgraded to Hold from Buy at Maxim
03/03/20 Maxim
Co-Diagnostics downgraded to Hold from Buy at Maxim
FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

05/14/20 KeyBanc
Farfetch, Nordstrom, Revolve could be impacted by Amazon offering, says KeyBanc
03/30/20 Wells Fargo
Farfetch downgraded to Underweight from Equal Weight at Wells Fargo
02/28/20 KeyBanc
Farfetch price target lowered to $17 from $20 at KeyBanc
11/15/19 Credit Suisse
Farfetch price target lowered to $17 from $22 at Credit Suisse
CVET Covetrus
$11.25 /

+0.3 (+2.74%)

09/09/19 Goldman Sachs
Covetrus initiated with a Sell at Goldman Sachs
08/14/19 Stifel
Covetrus price target lowered to $18 from $30 at Stifel
08/14/19 William Blair
Covetrus risk/reward 'intriguing' after selloff, says William Blair
05/23/19 Guggenheim
Covetrus initiated with a Neutral at Guggenheim
ETON Eton Pharmaceuticals
$5.20 /

+0.03 (+0.58%)

03/30/20 H.C. Wainwright
Eton Pharmaceuticals price target raised to $26 from $23 at H.C. Wainwright
01/28/20 H.C. Wainwright
Eton Pharmaceuticals price target raised to $23 from $21 at H.C. Wainwright
10/23/19 H.C. Wainwright
Eton Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
09/20/19
Fly Intel: Top five analyst initiations
AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

05/05/20 Cowen
Aurinia Pharmaceuticals initiated with an Outperform at Cowen
03/16/20 H.C. Wainwright
Aurinia's voclosporin could get FDA approval in 1Q21, says H.C. Wainwright
01/10/20 Jefferies
Aurinia Pharmaceuticals initiated with a Buy at Jefferies
12/16/19 H.C. Wainwright
Aurinia Pharmaceuticals price target raised to $32 from $25 at H.C. Wainwright
VVI Viad
$16.65 /

+0.71 (+4.45%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

05/06/20 Cantor Fitzgerald
TG Therapeutics price target raised to $35 from $19 at Cantor Fitzgerald
05/05/20 B. Riley FBR
TG Therapeutics price target raised to $29 from $25 at B. Riley FBR
05/05/20 H.C. Wainwright
TG Therapeutics price target raised to $32 from $24 at H.C. Wainwright
01/17/20 B. Riley FBR
TG Therapeutics price target raised to $25 from $17 at B. Riley FBR
YTEN Yield10 Bioscience
$4.92 /

-0.02 (-0.40%)

VVI Viad
$16.65 /

+0.71 (+4.45%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

OPRT Oportun Financial
$6.00 /

-0.25 (-4.00%)

OCUL Ocular Therapeutix
$6.01 /

-0.3 (-4.75%)

NEWR New Relic
$58.22 /

+1.62 (+2.86%)

GLOB Globant
$111.38 /

+3.1 (+2.86%)

FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

ETON Eton Pharmaceuticals
$5.20 /

+0.03 (+0.58%)

DENN Denny's
$8.77 /

-0.035 (-0.40%)

DDS Dillard's
$22.94 /

-1.15 (-4.77%)

CVET Covetrus
$11.25 /

+0.3 (+2.74%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

AEYE AudioEye
$8.88 /

+0.71 (+8.69%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

  • 15
    May
REGN Regeneron
$569.80 /

-7.58 (-1.31%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

YTEN Yield10 Bioscience
$4.92 /

-0.02 (-0.40%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

DENN Denny's
$8.77 /

-0.035 (-0.40%)

CVET Covetrus
$11.25 /

+0.3 (+2.74%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

TGTX TG Therapeutics
$19.90 /

-0.72 (-3.49%)

REGN Regeneron
$569.80 /

-7.58 (-1.31%)

FTCH Farfetch
$15.94 /

+0.35 (+2.25%)

DENN Denny's
$8.77 /

-0.035 (-0.40%)

CODX Co-Diagnostics
$22.19 /

-1.2 (-5.13%)

AUPH Aurinia Pharmaceuticals
$17.39 /

-0.19 (-1.08%)

AMAT Applied Materials
$54.51 /

+2.98 (+5.78%)

ACB Aurora Cannabis
$6.61 /

+0.79 (+13.57%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.